NeoGenomics NEO Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 43.2%-0.1pp | 43.2%-0.2pp | 43.5%-0.5pp | 43.9%-0.4pp | 44.3%+0.4pp | |
| Operating margin | -14.2%+1.7pp | -15.9%+1.1pp | -17%-0.4pp | -16.7%-3.4pp | -13.3%+0.7pp | |
| Net margin | -13.3%+1.6pp | -14.9%+1.1pp | -16%-0.9pp | -15.1%-3.6pp | -11.5%+0.4pp | |
| EBITDA margin | -5.3%+1.3pp | -6.6%+0.6pp | -7.2%-0.9pp | -6.4%-3.8pp | -2.6%+0.4pp | |
| Returns | ||||||
| Return on equity | -11.6%+0.9pp | -12.4%+0.6pp | -13%-1.2pp | -11.8%-3.2pp | -8.6%0.0pp | |
| Return on assets | -6.7%+0.5pp | -7.2%+0.3pp | -7.5%-0.7pp | -6.9%-2.1pp | -4.8%0.0pp | |
| Return on invested capital | -15.7%-0.7pp | -15%+2.8pp | -17.8%-1.4pp | -16.5%-2.3pp | -14.1%-1.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.4×0.0× | |
| Inventory turnover | 14.2×-0.7× | 14.9×-0.2× | 15.2×+1.7× | 13.5×-1.5× | 15×+0.4× | |
| Liquidity | ||||||
| Current ratio | 4.4×+0.2× | 4.3×+0.4× | 3.9×0.0× | 3.9×+1.9× | 2.1×+0.1× | |
| Quick ratio | 4.1×+0.1× | 3.9×+0.3× | 3.6×0.0× | 3.6×+1.6× | 1.9×+0.1× | |
| Cash ratio | 1.7×-0.1× | 1.8×+0.1× | 1.7×+0.1× | 1.5×+0.3× | 1.2×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×-0.2× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0×-0.1× | |
| Interest coverage | -38.9×-8.0× | -30.9×-5.6× | -25.3×-5.5× | -19.8×-6.1× | -13.6×+0.3× | |
| Per Share | ||||||
| Book value per share | $6.42-1.8% | $6.530.0% | $6.53-2.2% | $6.67-4.3% | $6.97-2.1% | |
| Valuation | ||||||
| Market capitalization | $1.79B+98.5% | $1.52B+52.6% | $997.26M+7.2% | $930.46M-23.7% | $1.22B-42.4% | |
| Enterprise value | $1.71B+177% | $1.43B+58.5% | $901.97M+6.6% | $846.41M-9.6% | $935.84M-53.5% | |
| Price / sales | 2.4×+1.1× | 2.1×+0.7× | 1.4×+0.1× | 1.4×-0.5× | 1.8×-1.4× | |
| Price / book | 2.2×+1.1× | 1.8×+0.6× | 1.2×+0.1× | 1.1×-0.3× | 1.4×-1.0× | |
| EV / sales | 2.3×+1.4× | 2×+0.7× | 1.3×0.0× | 1.2×-0.2× | 1.4×-1.7× | |
| Earnings yield | -5.5%+3.1pp | -7.1%+4.3pp | -11.4%-0.2pp | -11.2%-4.8pp | -6.4%-2.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are NeoGenomics's profit margins?
- NeoGenomics (NEO) runs a 43.2% gross margin and a -14.2% operating margin, with a -13.3% net margin.
- Where do NeoGenomics's ratios come from?
- Every ratio is computed from NeoGenomics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
